- Home
- Equipment
- usa arizona
- expression of genes
Refine by
Expression Of Genes Equipment Supplied In Usa Arizona
8 equipment items found
Manufactured by:GenoSensor Corporation based inTempe, ARIZONA (USA)
GenoExplorer gene expression microarray is a high quality, completely customizable microarray that provides a cost effective and timely solution for microarray users. Oligonucleotide probes can be defined and designed by the user and supported by our bioinformatics and technical ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Increased Clarity for Difficult-to-Diagnose Melanocytic Lesions. MyPath Melanoma and DecisionDx DiffDx Melanoma gene expression profile (GEP) tests are designed to provide objective information to aid in the diagnosis and inform management decisions for patients with ambiguous melanocytic ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Castle Biosciences offers DecisionDx-PRAME gene expression profile testing to assess expression of the PRAME (preferentially expressed antigen in melanoma) gene. DecisionDx-PRAME is an optional, additional test that can be run on the same sample as your DecisionDx®-UM GEP (gene ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Our DecisionDx-CMSeq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue. The test includes hotspot mutations in the genes BRAF, NRAS and ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Our DecisionDx-UMSeq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma. Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as possible about a uveal melanoma tumor from a single ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Predicting Individual Risk of Metastasis: DecisionDx-SCC is now commercially available. DecisionDx-SCC is clinically validated as a significant predictor of metastasis and the strongest predictor of risk compared to traditional clinical and pathological factors. DecisionDx-SCC complements traditional prognostic risk assessment factors, enabling more informed choices about treatment and follow-up ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Uveal melanoma, commonly known as ocular or choroidal melanoma, is a rare cancer of the eye with approximately 2,000 patients diagnosed annually in the U.S. At the time of initial diagnosis, approximately 97% of patients are free of metastasis. However, within five years, approximately 30% of patients will develop metastasis – rising to nearly 50% in the following ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Predicting Individual Risk of Recurrence or Metastasis: DecisionDx-Melanoma was designed to address the need for a more accurate predictor of metastatic risk in patients diagnosed with cutaneous (skin) melanoma. ...